Sulfo-SPDB-DGN462

Sulfo-SPDB-DGN462

• UNSPSC Description: Sulfo-SPDB-DGN462 is a agent-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
• Target Antigen: Drug-Linker Conjugates for ADC
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/sulfo-spdb-dgn462.html
• Solubility: 10 mM in DMSO
• Smiles: O=C1N2[C@](CC3=C2C=CC=C3)([H])CNC4=CC(OCC5=CC(N(C(C(C)(C)SSCCC(S(=O)(O)=O)C(ON6C(CCC6=O)=O)=O)=O)CCOCCOCCOC)=CC(COC7=C(OC)C=C8C(N9[C@](CC%10=C9C=CC=C%10)([H])C=NC8=C7)=O)=C5)=C(OC)C=C14
• Molecular Weight: 1251.40
• References & Citations: [1]Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported